This Biotech Breakout Star is Our Growth Stock of the Week

NASDAQ: VRTX | Vertex Pharmaceuticals Inc. News, Ratings, and Charts

VRTX – Vertex Pharmaceuticals (VRTX) is a high-quality biotech stock that is quite cheap with impressive growth prospects. Read on to find out why it’s our growth stock of the week….

The stock market is in the midst of a powerful and blistering rally.

There’s a vigorous debate about whether a new bull market has begun or if is this just a head fake within a bear market. Even among those who agree about the destination – disagree about how the market gets there.

Rather than dive into these arguments, it’s better to focus on high-conviction ideas. One of these is that the biotech sector has bottomed even if the broader market may not have. In the biotech sector, investors should target high-quality stocks with strong pipelines. 

Vertex Pharmaceuticals (VRTX) is a high-quality biotech with these characteristics. Read on to find out why it’s our growth stock of the week…

Company Background

VRTX discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. The company also focuses on developing treatments for pain, type 1 diabetes, inflammatory diseases, influenza, and other rare diseases.

The company’s cystic fibrosis drugs are poised to continue dominating the market for the foreseeable future due to the disease-modifying potential of the drugs, consistent use by patients, and very little competition. VRTX combination therapies also have lengthy patents, which protect its cystic fibrosis portfolio from generics. There is also potential for its non-cystic fibrosis pipeline, which has exposure to promising areas, such as AAT deficiency, sickle cell disease, and beta-thalassemia.

Growth

One reason to favor biotech and pharmaceutical stocks in this environment is that their earnings prospects are less connected to factors like economic growth and monetary policy. This is because healthcare spending is related to trends like demographics and increasing government spending on healthcare.

In particular, VRTX is the only pharma company with a treatment for cystic fibrosis. And, this should continue to grow at a healthy pace as it gets approval into new markets and for younger ages. The company’s pipeline is also well-stocked with candidates for diabetes, including a treatment that would replace pancreatic cells that just delivered promising results in clinical trials. 

Value

Despite this impressive growth, VRTX is quite cheap with a forward P/E of 18 which is slightly higher than the S&P 500’s forward P/E. Yet, this is justified given that VRTX has much less risk of an earnings decline due to being in the healthcare industry and its strong pipeline of products.

The company also stands out with its 30% profit margins which are 2.5x the S&P 500’s 12.2% profit margins. Further, VRTX has more pricing power and is less subject to inflationary pressures which some expect to lead to some margin compression for many stocks.

POWR Ratings

VRTX has an overall grade of A which equates to a strong Buy rating in the POWR Ratings service. A-rated stocks have posted an average annual performance of 31.1% which compares favorably to the S&P 500’s average annual gain of 8.0%. 

VRTX also has strong component grades including an A for Quality due to 11 out of 19 analysts covering the stock having a Strong Buy rating with only 2 having a Sell rating. It’s also regarded as one of the top companies in the space due to its dominance of the CF market and strong pipeline of potential, blockbuster treatments. Click here to see more of VRTX’s POWR Ratings.

9 “MUST OWN” Growth Stocks

What makes them “MUST OWN“?

All 9 picks have strong fundamentals and are experiencing tremendous momentum. They also contain a winning blend of growth and value attributes that generates a catalyst for serious outperformance.

Even more important, each recently earned a Buy rating from our coveted POWR Ratings system where the A rated stocks have gained +31.10% a year.

Click below now to see these top performing stocks with exciting growth prospects:

9 “MUST OWN” Growth Stocks


VRTX shares were trading at $302.57 per share on Tuesday morning, down $2.96 (-0.97%). Year-to-date, VRTX has gained 37.78%, versus a -9.33% rise in the benchmark S&P 500 index during the same period.


About the Author: Jaimini Desai


Jaimini Desai has been a financial writer and reporter for nearly a decade. His goal is to help readers identify risks and opportunities in the markets. He is the Chief Growth Strategist for StockNews.com and the editor of the POWR Growth and POWR Stocks Under $10 newsletters. Learn more about Jaimini’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
VRTXGet RatingGet RatingGet Rating
IBBGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Investor Alert: Healthy Pause for Stock Market

This recent pullback very much looks like a “healthy pause” for the stock market as the S&P 500 (SPY) comes off recent highs. What is the cause of the pause? How long will it last? What happens afterwards? And how to make money in this market? Steve Reitmeister will answer all these questions and more in his latest market commentary below...

3 Gold Stocks to Buy Poised for Success

With expected interest rate cuts, surging gold jewelry demand, and ongoing geopolitical conflicts, gold prices have hit record highs this year. Thus, it could be wise to buy fundamentally sound gold stocks Centerra Gold (CGAU), Gold Fields (GFI), and Kinross Gold (KGC), which are well-poised for success. Keep reading…

3 Internet Stocks Poised up for Rapid Growth in April

The internet industry thrives thanks to expanding usage, its transformative impact on work and communication globally, advancements in 5G, and its widespread integration into daily life. Hence, it could be wise to consider adding internet stocks ATRenew (RERE), Chegg (CHGG), and 1-800-FLOWERS.COM (FLWS) to one’s portfolio for growth. Read on...

TXN vs. INTC Earnings Alert - Which Chip Stock Will Surge Ahead?

Growing applications of chips across diverse end-use sectors and emerging digital technologies will shape the growth trajectory of the semiconductor industry and create several opportunities for industry players. So, let’s analyze Texas Instruments (TXN) and Intel (INTC) to determine which of these chip stocks will surge following their first-quarter earnings. Read more...

Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Read More Stories

More Vertex Pharmaceuticals Inc. (VRTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VRTX News